February 01, 2018
The US Food and Drug Administration (FDA) has approved the oral liquid therapy Firvanq (vancomycin hydrochloride) for the treatment of Clostridium difficile-associated diarrhea (CDAD) and Staphylococcus aureus-associated enterocolitis.
Oral formulations of the antibiotic vancomycin are used to treat gastroinestinal infections. The approval is expected to improve patient access to vancomycin oral liquid therapy and reduce pharmacist burden by no longer having to compound liquid formulation. “As a practicing infectious disease physician treating many patients with CDAD, having an FDA-approved vancomycin oral liquid formulation that is affordable and accessible to my patients is very beneficial,” said Stuart Johnson, MD, of Loyola University Medical Center, in a press release.
Firvanq will be available in 25 mg/mL and 50 mg/mL strengths in 150 mL and 300 mL sizes. It is set to be launched on April 2, 2018.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here